Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGON NASDAQ:IDYA NASDAQ:LCAP NYSE:PACS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGONCG Oncology$26.10-0.2%$26.23$14.80▼$40.47$1.99B0.86932,270 shs983,154 shsIDYAIDEAYA Biosciences$24.50-1.3%$21.48$13.45▼$44.42$2.17B0.03970,209 shs883,552 shsLCAPLionheart Acquisition Co. II$27.43+0.8%$10.38$8.94▼$11.70$506.23M0.08102,067 shs16,063 shsPACSPACS Group$11.70+2.4%$11.60$8.28▼$43.92$1.74B0.92543,815 shs379,503 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGONCG Oncology-0.68%-8.15%+1.32%+16.85%-21.27%IDYAIDEAYA Biosciences+5.08%+12.40%+14.00%+30.68%-41.18%LCAPLionheart Acquisition Co. II+0.69%+1.51%+3.83%+12.55%+7,013.08%PACSPACS Group-3.99%-7.37%-9.60%+19.09%-66.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGONCG Oncology2.2411 of 5 stars4.51.00.00.02.00.80.0IDYAIDEAYA Biosciences4.1857 of 5 stars4.41.00.04.42.41.70.0LCAPLionheart Acquisition Co. IIN/AN/AN/AN/AN/AN/AN/AN/APACSPACS Group2.5656 of 5 stars3.41.00.00.01.60.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGONCG Oncology 3.08Buy$55.30111.88% UpsideIDYAIDEAYA Biosciences 2.86Moderate Buy$47.5594.06% UpsideLCAPLionheart Acquisition Co. II 0.00N/AN/AN/APACSPACS Group 2.86Moderate Buy$34.29193.04% UpsideCurrent Analyst Ratings BreakdownLatest LCAP, IDYA, CGON, and PACS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025IDYAIDEAYA BiosciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy7/16/2025CGONCG OncologyRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$68.00 ➝ $53.007/10/2025CGONCG OncologyThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$40.007/10/2025IDYAIDEAYA BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$25.007/9/2025IDYAIDEAYA BiosciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$57.00 ➝ $30.006/26/2025IDYAIDEAYA BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$44.006/26/2025IDYAIDEAYA BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$44.006/17/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$52.00 ➝ $56.005/22/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.005/19/2025CGONCG OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $52.005/2/2025CGONCG OncologyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$41.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGONCG Oncology$1.14M1,745.04N/AN/A$9.63 per share2.71IDYAIDEAYA Biosciences$7M306.53N/AN/A$12.25 per share2.00LCAPLionheart Acquisition Co. IIN/AN/A$1.33 per share20.64($2.85) per shareN/APACSPACS Group$3.56B0.50N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGONCG Oncology-$88.04M-$1.51N/AN/AN/A-15,945.17%-16.71%-16.24%8/14/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.59N/AN/AN/AN/A-29.28%-27.68%8/5/2025 (Estimated)LCAPLionheart Acquisition Co. II$3.21MN/A0.00∞N/AN/A-44.30%1.39%N/APACSPACS Group$112.87MN/A0.006.57N/AN/AN/AN/A8/11/2025 (Estimated)Latest LCAP, IDYA, CGON, and PACS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CGONCG Oncology-$0.49N/AN/AN/AN/AN/A8/11/2025Q3 2024PACSPACS Group$0.45N/AN/AN/AN/AN/A8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85N/AN/AN/A$3.48 millionN/A5/13/2025Q1 2025CGONCG Oncology-$0.36-$0.45-$0.09-$0.45$0.53 million$0.05 million5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75-$0.82-$0.07-$0.82$2.10 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGONCG OncologyN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ALCAPLionheart Acquisition Co. IIN/AN/AN/AN/AN/APACSPACS GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGONCG OncologyN/A30.9730.97IDYAIDEAYA BiosciencesN/A13.9213.92LCAPLionheart Acquisition Co. IIN/A0.050.05PACSPACS GroupN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGONCG Oncology26.56%IDYAIDEAYA Biosciences98.29%LCAPLionheart Acquisition Co. IIN/APACSPACS GroupN/AInsider OwnershipCompanyInsider OwnershipCGONCG Oncology7.40%IDYAIDEAYA Biosciences2.50%LCAPLionheart Acquisition Co. II19.40%PACSPACS GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGONCG Oncology6176.22 million70.58 millionOptionableIDYAIDEAYA Biosciences8087.58 million85.39 millionOptionableLCAPLionheart Acquisition Co. II318.45 million14.87 millionNot OptionablePACSPACS Group32,433152.40 millionN/AOptionableLCAP, IDYA, CGON, and PACS HeadlinesRecent News About These CompaniesDemocrats’ 2024 Autopsy Is Described as Avoiding the Likeliest Cause of DeathJuly 20, 2025 | nytimes.comActivist group’s CEO admits he was offered $20 million to hire demonstrators for anti-Trump ralliesJuly 18, 2025 | bizpacreview.comB‘Dawn of a new era’: 2025 mayor’s race among the most expensive in San Antonio historyJuly 18, 2025 | sanantonioreport.orgSHogg offers new details on battle with DNCJuly 18, 2025 | msn.comMuslim donors flood Mamdani’s campaign for NYC mayor, see national impactJuly 18, 2025 | msn.comPACS Group (NYSE:PACS) Trading Down 0.6% - Here's WhyJuly 17, 2025 | marketbeat.comGroup backing Vivek Ramaswamy urges New Yorkers to flee to OhioJuly 16, 2025 | msn.comNew labor-backed PAC pledges $50M in battleground House racesJuly 16, 2025 | msn.comIRS commissioner’s PAC paid research firms amid confirmation fightJuly 16, 2025 | msn.comFederal judge blocks Maine's voter-approved law capping donations to super PACsJuly 16, 2025 | mainepublic.orgMBacklash Erupts Over Right-Wing Group’s Attempt to Block Parthenon Marbles DealJuly 13, 2025 | news.artnet.comNNew anti-Mamdani PAC looks to raise $25MJuly 11, 2025 | crainsnewyork.comCSenate Republican PAC surpasses record by raising $85 million in first six months of off-yearJuly 9, 2025 | justthenews.comJNorthern Ireland engineering group sold to investorJuly 8, 2025 | insidermedia.comIConservative group takes on IRS a decade after Obama-era scandal and ‘vague’ standardJuly 8, 2025 | bizpacreview.comBWhich will be strongest conference in Group of Six in 2026? Comparing the Pac-12 to the AACJuly 8, 2025 | commercialappeal.comCBelfast-based engineering group PAC acquired by Watford-based investorJuly 8, 2025 | msn.comCorporate money falls flat in council races despite record $14M spentJuly 3, 2025 | crainsnewyork.comCKentucky ’26 Senate race already sees attack ads, PAC spending in GOP primaryJuly 2, 2025 | msn.comPAC Spending in Council Races More Than Doubled, Fueled by Money from DoorDash, Airbnb and UberJuly 2, 2025 | msn.comGroup claims 'gamefowl' PAC leaders seen on secret video at rural Oklahoma cockfightJuly 1, 2025 | tennessean.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLCAP, IDYA, CGON, and PACS Company DescriptionsCG Oncology NASDAQ:CGON$26.10 -0.04 (-0.15%) Closing price 04:00 PM EasternExtended Trading$26.08 -0.02 (-0.08%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.IDEAYA Biosciences NASDAQ:IDYA$24.50 -0.33 (-1.33%) Closing price 04:00 PM EasternExtended Trading$24.50 +0.00 (+0.02%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Lionheart Acquisition Co. II NASDAQ:LCAPLionheart Acquisition Corporation II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in PropTech sector. The company was incorporated in 2019 and is based in Miami, Florida.PACS Group NYSE:PACS$11.70 +0.27 (+2.36%) Closing price 03:58 PM EasternExtended Trading$11.65 -0.05 (-0.43%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
